NR4A1 and cancer: Given the effectiveness of endocrine treatment, including aromatase inhibitors and tamoxifen, in BC prevention, most patients with hormone receptor-positive BC would undergo endocrine treatment in the first five years to prevent cancer recurrence, which simultaneously lowers their risk of CBC [28,29,30].